Cardiotoxicity of anticancer treatments
@article{Ewer2015CardiotoxicityOA, title={Cardiotoxicity of anticancer treatments}, author={Michael S. Ewer and Steven M Ewer}, journal={Nature Reviews Cardiology}, year={2015}, volume={12}, pages={547-558} }
Patients with cancer can experience adverse cardiovascular events secondary to the malignant process itself or its treatment. Patients with cancer might also have underlying cardiovascular illness, the consequences of which are often exacerbated by the stress of the tumour growth or its treatment. With the advent of new treatments and subsequent prolonged survival time, late effects of cancer treatment can become clinically evident decades after completion of therapy. The heart's extensive…
238 Citations
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
- Medicine, BiologyNature Reviews Cardiology
- 2020
The cardiotoxicity spectrum of cancer therapies has broadened and is gaining increasing importance with an ever-growing repertoire of therapeutics, and atrial fibrillation is emerging as the most relevant and practically challenging arrhythmia in patients with cancer.
Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection
- Biology, MedicineFrontiers in Cardiovascular Medicine
- 2022
There is an urgent need for cardioprotective therapies to reduce the clinical and subclinical cardiotoxicity onset and progression and to limit the acute or chronic manifestation of cardiac damages.
Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity
- Medicine, BiologyOxidative medicine and cellular longevity
- 2020
The progress of genetic research in illuminating the molecular mechanisms of cancer treatment-mediated cardiotoxicity is reviewed and insights for the research and development of new therapies to treat or even prevent cardiot toxicity in patients undergoing cancer treatment are provided.
Cardiooncology—dealing with modern drug treatment, long-term complications, and cancer survivorship
- Medicine, BiologyClinical & experimental metastasis
- 2021
This review focusses on acute and long-term cardiotoxic side effects of classical cytotoxic and selected modern drug treatments such as immune checkpoint inhibitors and discusses strategies for the diagnosis of treatment-related adverse cardiovascular effects in cancer patients.
Cardiotoxicity of Cancer Treatments: Focus on Anthracycline Cardiomyopathy
- Biology, MedicineArteriosclerosis, thrombosis, and vascular biology
- 2021
A focused review of the mechanisms proposed to underlie the development of anthracycline cardiomyopathy based on experimental data mostly in mouse models and insights into its pathogenesis may stimulate thedevelopment of new strategies to identify patients who are susceptible to anthrACYclineCardiotoxicities while permitting low cardiac risk patients to receive optimal treatment for their cancer.
Cardiovascular disease in survivors of childhood cancer
- MedicineCurrent opinion in pediatrics
- 2018
A deeper understanding of the mechanisms of their cardiotoxicity reveals that there is no ‘safe’ dose of anthracyclines, and the use of dexrazoxane is advocated to limit the cardiotoxic effects of anthRacycline chemotherapy.
ATVB IN FOCUS: Cardiovascular Effects of Anticancer Treatments/Agents
- Biology
- 2020
A focused review of the mechanisms proposed to underlie the development of anthracycline cardiomyopathy based on experimental data mostly in mouse models and insights into its pathogenesis may stimulate theDevelopment of new strategies to identify patients who are susceptible to anthrACYclineCardiotoxicities while permitting low cardiac risk patients to receive optimal treatment for their cancer.
Hypertension management in cardio-oncology
- MedicineJournal of Human Hypertension
- 2020
Hypertension in cardio-oncology is a leading cause of morbidity and mortality in cancer survivors second only to recurrent cancer and should be managed utilising the same treatment guidelines for the general population.
Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients
- Medicine, BiologyCardiac failure review
- 2019
The authors describe the mechanisms of cardiotoxicity induced by anthracyclines, which can lead to cardiovascular problems in up to 48% of patients who take them, and outline the recent advances in immunotherapies, which have revolutionised anticancer therapies.
References
SHOWING 1-10 OF 125 REFERENCES
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
- Medicine, BiologyNature Reviews Cardiology
- 2010
In an effort to maximize both quality of life and survival, cardiologists and oncologists should collaborate with the aim of balancing the risks of cardiotoxicity with the benefits of oncologic therapy.
Chemotherapy-induced cardiotoxicity: detection, prevention, and management.
- Medicine, BiologyThe Canadian journal of cardiology
- 2014
Cardiac Complications of Chemotherapy: Role of Biomarkers
- Medicine, BiologyCurrent Treatment Options in Cardiovascular Medicine
- 2014
Cardiac troponin elevation during chemotherapy allows us to identify patients who are more prone to develop myocardial dysfunction and cardiac events during follow up, giving the chance for a cardioprotective strategy in a selected population.
Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies
- MedicineBritish journal of haematology
- 2005
The most promising current strategies to limit or prevent anthracycline‐induced cardiotoxicity, as well as possible strategies to prevent existing cardiomyopathy from worsening are summarised.
Using cardiac biomarkers and treating cardiotoxicity in cancer.
- Medicine, BiologyFuture cardiology
- 2013
Cardiac troponin elevation during chemotherapy allows the identification of patients who are more prone to develop myocardial dysfunction and cardiac events during follow-up, giving the chance for a cardioprotective strategy in a selected population of cancer patients.
Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities.
- MedicineJournal of the National Cancer Institute
- 2014
This commentary highlights the key discussion points and overarching recommendations from a two-day workshop on the understanding of cancer treatment-related cardiotoxicity across basic and clinical science held in March 2013 in Bethesda, MD.
Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.
- MedicineJournal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2005
Type I chemotherapyrelated cardiac dysfunction, which directly involves the myocardium, is manifested by a decreased left-ventricular ejection fraction, and which may progress to congestive heart failure; this form is the focus of this brief commentary.
Clinical spectrum of anthracycline antibiotic cardiotoxicity.
- MedicineCancer treatment reports
- 1978
Late effects of anthracyclines are directly related to the degree of associated myocyte damage and include subclinical left ventricular dysfunction and overt heart failure and a common pathogenetic mechanism is proposed.
Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis.
- Medicine, BiologyEuropean journal of cancer
- 2013